Golden
AH Bio Fund

AH Bio Fund

Venture capital fund with a focus on early-stage startups at the intersection of computer science and life sciences, managed by Andreessen Horowitz.

AH Bio Fund is a series of two Limited Partnership, Venture Capital, Pooled Investment Funds managed by Andreessen Horowitz.

AH Bio Fund I, L.P. specializes in Series A, seed, early-stage startup investments. The fund seeks to invest in software related biology, biotech, and medicine companies at the intersection of computer science and life sciences, with a focus on digital therapeutics, cloud technology in biology, and computational medicine robot. AH Bio Fund I raised $200M across 67 investors. It was announced on November 18, 2015.

AH Bio Fund II, L.P was announced on Dec 14, 2017 . The Andreessen Horowitz' second bio fund is a $450 million investment fund focused on the intersection of biology and engineering. As with the first bio fund, they invest across seed to growth.

History

In 2015, the venture firm Andreessen Horowitz launched a $200 million fund located in Menlo Park, CA, to invest in software, biology, and medicine, led by its ninth general partner, Vijay Pande. The Official name of the fund is AH Bio Fund I LP . The fund managed to gather $200M (18 Nov 2015) from 67 investors .

AH Bio Fund II, L.P is a venture capital fund located in Menlo Park, CA that invests in early-stage healthcare-focused information technology companies. This Andreessen Horowitz sponsored fund is led by Vijay Pande, the chair of Stanford University's chemistry department. The fund is an extension of the firm's early-stage information technology investment program, but differs in its focus on the healthcare sector.

The focus is in computational biomedicine, applying AI and ML to diagnostics and therapeutics; new bio utilities or tools that make it easier to "read", "write" or edit and synthesize DNA, as well as making advances in bioengineering itself.

Investments

AH Bio Fund I LP

The fund isn't investing directly in traditional biotech. Instead, it's focused on software companies built to enable and address biotech ideas.

Vijay Pande is making about one Series A investment and 2-3 seed investments each quarter, on pace with other general partners at Andreessen Horowitz. The fund works closely with Y Combinator as the startup hub spots and grows more companies in the space as well.

AH Bio Fund II

Investments in software companies which can benefit from the reduction in the costs of data storage, computational power, sensors to measure biological data, and genetic sequencing. AH Bio Fund II has identified computational biomedicine, new scientific utilities, and network effects in healthcare as areas of specific investment interest.

Timeline

AH Bio Fund II

$450M

AH Bio Fund I LP

$200M

People

Name
Role
Related Golden topics

Ben Horowitz

Executive Officer

Marc Andreessen

Executive Officer

Scott Kupor

Chief Operating Officer

Vijay Pande

Partner

Further reading

Title
Author
Link
Type

Andreessen Horowitz has a new, $450 million bio fund

Web

Going Deeper Into Freenome

Web

Menlo Ventures dives into data-driven healthcare investing with its newest partner

Connie Loizos

Web

The One Health Company

Web

Top Silicon Valley VC Andreessen Horowitz is investing $450 million into biotech

Lydia Ramsey

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Apeel

Asimov

BioAge

CAMP4

Cardiogram

Ciitizen

Devoted

Freenome

Q

twoXAR

References